Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics May 19 | 2025Skye Partners for Obesity Development; May CHMP Agenda; Altimmune Initiates Ph2 Study in AUD; Zealand Appoints New CDO; Cytokinetics Presents Additional Aficamten Analyses; Ionis Ph3 Olezarsen Topline Data Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics May 18 | 2025Novo’s CEO Steps Down; Abbott Invests in Senseonics; Cellarity Hires Ex-Scholar Rock CFO Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 16 | 2025Lilly’s Two New Ph3 Orforglipron Trials; Abbott’s Libre Reduces Hospitalization Risk; Metsera Registers New Obesity Study; MetaVia and Galectin Q1 ’25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics May 14 | 2025Novo Partners with Septerna for Obesity Drug Development; GSK Acquires MASH Asset from Boston Pharma; Sernova Interim Cell Pouch Results; Found Integrates with LillyDirect and NovoCare; Cytokinetics Ph3 HCM Results; Lexicon, Fractyl, and Scholar Rock Q1 ’25 Earnings Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Other, Topics May 14 | 2025Obesity Spotlight: Novo’s Quest for Semaglutide Successor and Next Obesity Foundational TherapyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 13 | 2025Arrowhead and Altimmune Q1 ‘25 Earnings; Omada IPO; Dexcom Appoints New President; SELECT Post-Hoc Analysis; Madrigal Hosts Investor Call; Skye CB1 Inhibitor Analysis at ECO 2025 Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics May 13 | 2025Lilly Presents Zepbound vs Wegovy Ph3 Data; Metsera and Akero Q1 ‘25 Earnings; Madrigal Ph3 MASH Data at EASL 2025; Roche Invests in North Carolina Manufacturing Site Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, Topics May 09 | 2025Insulet, Senseonics, Skye, and Biocon Q1 ‘25 Earnings; Zealand and Roche Make it Official; Akero Presents MASH Data at EASL 2025; Lilly Initiates New Ph3 Tirzepatide Study in T1DM Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics May 08 | 2025Novo London, Zealand, MannKind, Xeris, and Viatris Q1 ‘25 Earnings; US Judge Supports FDA’s Removal of Lilly’s GLP-1RA From Shortage List; Lilly Makes Changes to Executive LeadershipPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics May 07 | 2025Beta Bionics Q1 ‘25 Earnings; MetaVia Presents MASH data at EASL 2025Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other, Topics May 07 | 2025Novo Q1 ‘25 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 06 | 2025Vertex, Biomea, and Esperion Q1 ‘25 Earnings; Oura Launches Glucose Feature Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 02 | 2025FDA accepts Oral Sema NDA; Dexcom and Amgen Q1 ‘25 Earnings; Lilly Launches New Mounjaro Campaign Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics May 01 | 2025Lilly and Madrigal Q1 ’25 Earnings; Wegovy Receives Preferred Status from CVSPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 30 | 2025Lilly Integrates with WeightWatchers, Partners with Creyon, and Initiates New Ph3 Orfo Trials; Tandem Q1 ’25 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 29 | 2025Novo Partners with Telehealth Providers; AstraZeneca, Pfizer, Novartis, and Regeneron Q1 ’25 Earnings; Abbott and Epic CGM Integration; Eversense 365 to Integrate with twiist AID SystemPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 28 | 2025Insulet Hires New CEO; Galmed Sublingual Semaglutide; Vutrisiran ATTR-CM CHMP Opinion Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 25 | 2025AbbVie Q1 ‘25 Earnings; Madrigal Hires Ex-Novartis CVRM Development LeadPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 25 | 2025Medtronic Seeks Interoperability; Roche, Viking, Sanofi, and Merck Q1 ‘25 Earnings; Zealand Enrolls First Patient in Ph2 T2DM Study; Esperion R&D Day 2025Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 23 | 2025Lilly’s Two New Ph3 Studies in Obesity; Ascletis Ph1 Obesity Study Topline Results; Zealand Hires Ex-Lilly Exec; Lilly Sues Compounders...Again Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
